Aimee L. Jackson

Aimee has worked in the field of RNA interference and oligonucleotide therapeutics for 18 years. She most recently served as vice president of research for miRagen Therapeutics, where she advanced three microRNA programs from initial concept to first-in-human clinical trials in less than five years. These programs encompassed diverse therapeutic areas and comprised both microRNA mimics and inhibitors. Two of these programs have advanced to Phase 2 clinical trials, including a fibrosis program for which Aimee served as the product development team lead. Prior to joining miRagen, Aimee led preclinical research at Regulus Therapeutics and Merck/Rosetta, where she served as molecular profiling lead for the development of siRNA-based therapeutics and played a lead role in the identification of siRNA design aspects for enhanced activity and specificity. Aimee received her Ph.D. from the University of Colorado Health Science Center.

She is known for her great love of reading, yoga, hiking, good food and good wine. Her affection for good food and wine ultimately led to her earning her Sommelier certification to more fully enjoy this passion.